Exact Sciences Co. (NASDAQ:EXAS) Position Lessened by OneAscent Financial Services LLC

OneAscent Financial Services LLC decreased its stake in Exact Sciences Co. (NASDAQ:EXAS) by 16.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,287 shares of the medical research company’s stock after selling 837 shares during the period. OneAscent Financial Services LLC’s holdings in Exact Sciences were worth $568,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in EXAS. City Holding Co. bought a new position in shares of Exact Sciences during the 4th quarter valued at approximately $26,000. Baldwin Brothers Inc. MA bought a new position in shares of Exact Sciences during the 4th quarter valued at approximately $46,000. NuWave Investment Management LLC grew its position in shares of Exact Sciences by 2,143.8% during the 4th quarter. NuWave Investment Management LLC now owns 359 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 343 shares during the period. ELM Advisors LLC bought a new position in shares of Exact Sciences during the 4th quarter valued at approximately $60,000. Finally, Trustcore Financial Services LLC bought a new position in shares of Exact Sciences during the 3rd quarter valued at approximately $59,000. 79.58% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Katherine S. Zanotti sold 20,000 shares of the stock in a transaction on Monday, December 14th. The shares were sold at an average price of $132.06, for a total transaction of $2,641,200.00. Following the transaction, the director now owns 40,171 shares of the company’s stock, valued at approximately $5,304,982.26. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Kevin T. Conroy sold 32,819 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $121.11, for a total transaction of $3,974,709.09. Following the transaction, the chief executive officer now directly owns 916,521 shares in the company, valued at approximately $110,999,858.31. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 115,210 shares of company stock worth $14,520,315. 1.80% of the stock is owned by insiders.

Shares of NASDAQ:EXAS opened at $145.37 on Thursday. The company’s fifty day moving average price is $131.88 and its 200-day moving average price is $105.25. The firm has a market capitalization of $21.87 billion, a price-to-earnings ratio of -65.78 and a beta of 1.65. Exact Sciences Co. has a one year low of $35.25 and a one year high of $152.68. The company has a debt-to-equity ratio of 0.68, a current ratio of 6.35 and a quick ratio of 6.04.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Sunday, November 1st. The medical research company reported ($1.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.95). The company had revenue of $408.40 million during the quarter, compared to the consensus estimate of $337.43 million. Exact Sciences had a negative return on equity of 11.71% and a negative net margin of 25.27%. Exact Sciences’s quarterly revenue was up 86.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.31) EPS. As a group, equities research analysts expect that Exact Sciences Co. will post -1.22 EPS for the current year.

A number of research firms have recently weighed in on EXAS. TheStreet raised shares of Exact Sciences from a “d+” rating to a “c” rating in a research report on Thursday, October 15th. Robert W. Baird upped their price target on shares of Exact Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Wednesday, October 28th. Canaccord Genuity upped their price target on shares of Exact Sciences from $160.00 to $165.00 and gave the company a “buy” rating in a research note on Tuesday. They noted that the move was a valuation call. BidaskClub cut shares of Exact Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, January 6th. Finally, Oppenheimer upped their price target on shares of Exact Sciences from $115.00 to $150.00 in a research note on Wednesday, October 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $127.20.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer.

Featured Article: CAC 40 Index

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.